|
1
|
Tatum JL, Kelloff GJ, Gillies RJ, Arbeit
JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia
AJ, et al: Hypoxia: importance in tumor biology, noninvasive
measurement by imaging and value of its measurement in the
management of cancer therapy. Int J Radiat Biol. 82:699–757. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Harris AL: Hypoxia-a key regulatory factor
in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nordsmark M, Overgaard M and Overgaard J:
Pretreatment oxygenation predicts radiation response in advanced
squamous cell carcinoma of the head and neck. Radiother Oncol.
41:31–39. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vaupel P and Mayer A: Hypoxia in cancer:
Significance and impact on clinical outcome. Cancer Metastasis Rev.
26:225–239. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fyles A, Milosevic M, Hedley D, Pintilie
M, Levin W, Manchul L and Hill RP: Tumor hypoxia has independent
predictor impact only in patients with node-negative cervix cancer.
J Clin Oncol. 20:680–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee DJ, Moini M, Giuliano J and Westra WH:
Hypoxic sensitizer and cytotoxin for head and neck cancer. Ann Acad
Med Singapore. 25:397–404. 1996.PubMed/NCBI
|
|
7
|
Shibamoto Y, Takahashi M and Abe M: A
phase I study of a hypoxic cell sensitizer KU-2285 in combination
with conventional radiotherapy. Radiother Oncol. 40:55–58. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hassan Metwally MA, Ali R, Kuddu M,
Shouman T, Strojan P, Iqbal K, Prasad R, Grau C and Overgaard J:
IAEA-HypoX. A randomized multicenter study of the hypoxic
radiosensitizer nimorazole concomitant with accelerated
radiotherapy in head and neck squamous cell carcinoma. Radiother
Oncol. 116:15–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drzymala RE, Wasserman TH, Won M, Shaw E,
Cmelak AJ, Loeffler J and Souhami L; Radiation Therapy Oncology
Group, : A phase I-B trial of the radiosensitizer: Etanidazole
(SR-2508) with radiosurgery for the treatment of recurrent
previously irradiated primary brain tumors or brain metastases
(RTOG Study 95–02). Radiother Oncol. 87:89–92. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Overgaard J, Hansen HS, Overgaard M,
Bastholt L, Berthelsen A, Specht L, Lindeløv B and Jørgensen K: A
randomized double-blind phase III study of nimorazole as a hypoxic
radiosensitizer of primary radiotherapy in supraglottic larynx and
pharynx carcinoma. results of the danish head and neck cancer study
(DAHANCA) Protocol 5–85. Radiother Oncol. 46:135–146. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He ZY, Li FY, Tong Q, Liao ZW, Guan XX and
Wang Y: Concurrent chemoradiotherapy with sodium glycididazole and
cisplatin for local advanced nasopharyngeal carcinoma. Nan Fang Yi
Ke Da Xue Xue Bao. 28:2038–2040. 2008.(In Chinese). PubMed/NCBI
|
|
12
|
Zeng YC, Wu R, Xu ZG, Zhang XY, Fan GL, Wu
LN, Wang YM, Hao SH, Zheng W, Chen XD, et al: Safety and
radiation-enhancing effect of sodium glycididazole in
locoregionally advanced laryngeal cancers previously treated with
platinum-containing chemotherapy regimens: A preliminary report.
Cancer Radiother. 14:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li MY, Liu JQ, Chen DP, Qi B, Liang YY and
Yin WJ: Glycididazole sodium combined with radiochemotherapy for
locally advanced nasopharyngeal carcinoma. Asian Pac J Cancer Prev.
15:2641–2646. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nordsmark M, Bentzen SM, Rudat V, Brizel
D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J,
Terris DJ and Overgaard J: Prognostic value of tumor oxygenation in
397 head and neck tumors after primary radiation therapy. An
international multi-center study. Radiother Oncol. 77:18–24. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koukourakis MI, Bentzen SM, Giatromanolaki
A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E and
Harris AL: Endogenous markers of two separate hypoxia response
pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase
9) are associated with radiotherapy failure in head and neck cancer
patients recruited in the CHART randomized trial. J Clin Oncol.
24:727–735. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Overgaard J: Hypoxic radiosensitization:
Adored and ignored. J Clin Oncol. 25:1–4074. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Overgaard J, Eriksen JG, Nordsmark M,
Alsner J and Horsman MR; Danish Head and Neck Cancer Study Group, :
Plasma osteopontin, hypoxia and response to the hypoxia sensitiser
nimorazole in radiotherapy of head and neck cancer: Results from
the DAHANCA 5 randomised double-blind placebo-controlled trial.
Lancet Oncol. 6:757–764. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lim AM, Rischin D, Fisher R, Cao H, Kwok
K, Truong D, McArthur GA, Young RJ, Giaccia A, Peters L and Le QT:
Prognostic significance of plasma osteopontin in patients with
locoregionally advanced head and neck squamous cell carcinoma
treated on TROG 02.02 phase III trial. Clin Cancer Res. 18:301–307.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang J, Liu MZ, Cai L, Hu YH, Liu H, Li QQ
and Cui NJ: Phase II clinical trial of sodium glyci-didazole
(CM-Na) combined with concurrent radiochemotherapy for advanced
esophageal carcinoma. Ai Zheng. 27:622–666. 2008.(In Chinese).
PubMed/NCBI
|
|
20
|
Zhang Q, Wang DQ and Wu YF: Sodium
glycididazole enhances the efficacy of combined iodine-125 seed
implantation and chemotherapy in patients with non small-cell lung
cancer. Oncol Lett. 9:2335–2340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu MZ, He LR, Lu TX, Chen YY, Hu YH, Cui
NJ, Xu GZ, Gao L, Xiao GL, Zhang SW, et al: Effect of hypoxic
radiosensitizer sodium glycididazole on long-term result of
radiotherapy for nasopharyngeal carcinoma. Zhonghua Zhong Liu Za
Zhi. 28:932–937. 2006.(In Chinese). PubMed/NCBI
|
|
22
|
Liu CX, Wei GL and Xiao SH:
Pharmacokinetics of sodium bimetrondazole glycinate in mice and
rats. Yao Xue Xue Bao. 35:770–773. 2000.(In Chinese). PubMed/NCBI
|
|
23
|
Le QT, Sutphin PD, Raychaudhuri S, Yu SC,
Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC and Giaccia AJ:
Identification of osteopontin as a prognostic plasma marker for
head and neck squamous cell carcinomas. Clin Cancer Res. 9:59–67.
2003.PubMed/NCBI
|
|
24
|
Toustrup K, Sørensen BS, Lassen P, Wiuf C,
Alsner J and Overgaard J; Danish Head and Neck Cancer Group
(DAHANCA), : Gene expression classifier predicts for hypoxic
modification of radiotherapy with nimorazole in squamous cell
carcinomas of the head and neck. Radiother Oncol. 102:122–129.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tran LB, Bol A, Labar D, Cao-Pham TT,
Jordan B, Grégoire V and Gallez B: Predictive value of (18)F-FAZA
PET imaging for guiding the association of radiotherapy with
nimorazole: A preclinical study. Radiother Oncol. 114:189–194.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng XL, Gao JG and Zhang H: In vitro
radiosensitization effect of sodium glycididazol on V79 cells.
Journal of Radiation Research and Radiation Processing. 13:213–218.
1994.
|
